PPTD.F Stock Overview
A biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PeptiDream Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥17.15 |
| 52 Week High | JP¥18.00 |
| 52 Week Low | JP¥8.56 |
| Beta | 0.53 |
| 1 Month Change | 0.88% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -31.29% |
| 5 Year Change | -64.19% |
| Change since IPO | -82.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| PPTD.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -6.5% | -4.0% |
| 1Y | n/a | 1.3% | 24.0% |
Return vs Industry: Insufficient data to determine how PPTD.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PPTD.F performed against the US Market.
Price Volatility
| PPTD.F volatility | |
|---|---|
| PPTD.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PPTD.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PPTD.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 735 | Patrick Crawford Reid | www.peptidream.com |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.
PeptiDream Inc. Fundamentals Summary
| PPTD.F fundamental statistics | |
|---|---|
| Market cap | US$2.17b |
| Earnings (TTM) | US$109.22m |
| Revenue (TTM) | US$304.87m |
19.7x
P/E Ratio7.1x
P/S RatioIs PPTD.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPTD.F income statement (TTM) | |
|---|---|
| Revenue | JP¥47.77b |
| Cost of Revenue | JP¥12.24b |
| Gross Profit | JP¥35.53b |
| Other Expenses | JP¥18.41b |
| Earnings | JP¥17.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 132.05 |
| Gross Margin | 74.37% |
| Net Profit Margin | 35.83% |
| Debt/Equity Ratio | 34.7% |
How did PPTD.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 17:10 |
| End of Day Share Price | 2024/12/11 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PeptiDream Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Fumiyoshi Sakai | Credit Suisse |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |